Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 12Carcinoma, Non-Small-Cell Lung 6Lung Neoplasms 5Breast Diseases 4Thoracic Neoplasms 3Respiratory Tract Neoplasms 3Neoplasms 3Lung Diseases 3Bronchial Neoplasms 3Neoplasms, Glandular and Epithelial 2Neoplasms by Histologic Type 2Melanoma 2Kidney Neoplasms 2Endocrine Gland Neoplasms 2Digestive System Neoplasms 2Respiratory Tract Diseases 1Ovarian Neoplasms 1Ovarian Diseases 1Neoplasms by Site 1Mammary Neoplasms, Animal 1Hodgkin Disease 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Bronchogenic 1Advanced Breast Cancer 1

Interventions

Fulvestrant 13Letrozole 6Anastrozole 5palbociclib 4exemestane 3Injections 3Docetaxel 3Paclitaxel 2Goserelin 2Dasatinib 2Capecitabine 2Alpelisib 2AZD9833 2vandetanib 1ribociclib 1irinotecan sucrosofate 1entinostat 1elacestrant 1cediranib 1abemaciclib 1XMT-1522 1Vinorelbine 1Sirolimus 1Ritonavir 1Lead 1Itraconazole 1Immunotherapy, Adoptive 1Everolimus 1Decitabine 1Combined Modality Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Breast Cancer × entinostat × Clear all
NCT03538171 2021-07-09

Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer

Taizhou EOC Pharma Co., Ltd.

Phase 3 Unknown
375 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡